AmoyDx Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
1,175
- Stock Symbol
-
300685
- Investments
-
2
- Share Price
-
$2.73
- (As of Friday Closing)
AmoyDx General Information
Description
Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.
Contact Information
Website
www.amoydx.comCorporate Office
- Number 39 Dingshan Road, Haicang District
- Xiamen, Fujian 361000
- China
Corporate Office
- Number 39 Dingshan Road, Haicang District
- Xiamen, Fujian 361000
- China
AmoyDx Stock Performance
As of 13-Nov-2026, AmoyDx’s stock price is $2.73. Its current market cap is $1.06B with 390M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.73 | $2.85 | $2.30 - $3.50 | $1.06B | 390M | 10M | $0.13 |
AmoyDx Financials Summary
As of 30-Sep-2026, AmoyDx has a trailing 12-month revenue of $174M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,088,299 | 971,507 | 1,103,287 | 1,116,343 |
| Revenue | 174,370 | 166,553 | 154,547 | 147,495 |
| EBITDA | 53,558 | 60,773 | 44,668 | 47,128 |
| Net Income | 50,188 | 50,235 | 35,519 | 36,960 |
| Total Assets | 336,452 | 335,535 | 282,846 | 272,957 |
| Total Debt | 25,095 | 15,522 | 7,843 | 7,996 |
AmoyDx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AmoyDx Comparisons
Industry
Financing
Details
AmoyDx Competitors (12)
One of AmoyDx’s 12 competitors is Bio-Rad Laboratories, a Corporation company based in Hercules, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories | Corporation | Hercules, CA | ||||
| Biodesix | Formerly VC-backed | Louisville, CO | ||||
| Coyote Bioscience Co., Ltd. | Venture Capital-Backed | Beijing, China | ||||
| Insight Molecular Diagnostics | Formerly VC-backed | Nashville, TN | ||||
| Indivumed Therapeutics | Private Debt Financed | Hamburg, Germany |
AmoyDx Patents
AmoyDx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025140181-A1 | Method for simultaneously analyzing genetic information and epigenetic information | Inactive | 28-Dec-2023 | ||
| EP-4328920-A1 | Microsatellite instability detection method based on second-generation sequencing | Pending | 20-Apr-2021 | ||
| EP-4328920-A4 | Microsatellite instability detection method based on second-generation sequencing | Pending | 20-Apr-2021 | ||
| WO-2022222668-A1 | Microsatellite instability detection method based on second-generation sequencing | Inactive | 20-Apr-2021 | ||
| WO-2022161272-A1 | Biomarker group for detecting population microsatellite instability, and application of biomarker group | Inactive | 27-Jan-2021 | C12Q1/6888 |
AmoyDx Signals
AmoyDx Investments (2)
AmoyDx’s most recent deal was a Early Stage VC with Salus BioMed for . The deal was made on 10-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Salus BioMed | 10-Oct-2025 | Early Stage VC | Diagnostic Equipment | ||
| Universal Sequencing Technology | 24-May-2018 | Early Stage VC | Discovery Tools (Healthcare) |
AmoyDx ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
23.28 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
AmoyDx FAQs
-
When was AmoyDx founded?
AmoyDx was founded in 2008.
-
Where is AmoyDx headquartered?
AmoyDx is headquartered in Xiamen, China.
-
What is the size of AmoyDx?
AmoyDx has 1,175 total employees.
-
What industry is AmoyDx in?
AmoyDx’s primary industry is Biotechnology.
-
Is AmoyDx a private or public company?
AmoyDx is a Public company.
-
What is AmoyDx’s stock symbol?
The ticker symbol for AmoyDx is 300685.
-
What is the current stock price of AmoyDx?
As of 13-Nov-2026 the stock price of AmoyDx is $2.73.
-
What is the current market cap of AmoyDx?
The current market capitalization of AmoyDx is $1.06B.
-
What is AmoyDx’s current revenue?
The trailing twelve month revenue for AmoyDx is $174M.
-
Who are AmoyDx’s competitors?
Bio-Rad Laboratories, Biodesix, Coyote Bioscience Co., Ltd., Insight Molecular Diagnostics, and Indivumed Therapeutics are some of the 12 competitors of AmoyDx.
-
What is AmoyDx’s annual earnings per share (EPS)?
AmoyDx’s EPS for 12 months was $0.13.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process